Almirall

More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study

Retrieved on: 
Sunday, March 10, 2024
Diagnosis, Pigment, LLY, Weill Cornell Medicine, Atopic dermatitis, Health equity, Alaska Natives, Patient, Education, PDCA, Advocate, Diversity, Adherence, Immunology, Research, American Academy, Human, Weill Cornell Medical Center, Dermatitis, African, Skin, Safety, Lilly, Eli Lilly and Company, AAD, Health, IGA, Almirall, Pharmaceutical industry

In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief.

Key Points: 
  • In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief.
  • These late-breaking results from a Phase 3 study are being presented today at the American Academy of Dermatology (AAD) Annual Meeting.
  • "People with skin of color are disproportionately affected by atopic dermatitis, often experiencing more severe symptoms, a delay in diagnosis and a lengthier timeframe to find appropriate treatment.
  • "With these initial results, Lilly is taking a step toward investigating the needs of people with skin of color affected by atopic dermatitis."

Absci Appoints Professor Sir Mene Pangalos to its Board of Directors

Retrieved on: 
Wednesday, January 10, 2024
Neuroscience, Royal Society, Patient, Almirall, Medicine, Science, Francis Crick Institute, University, Executive, Drug discovery, Royal, Drug development, Therapy, Translation, AstraZeneca, Biopharmaceutical

In addition to joining Absci’s Board, Sir Pangalos will co-chair Absci’s Scientific Advisory Board.

Key Points: 
  • In addition to joining Absci’s Board, Sir Pangalos will co-chair Absci’s Scientific Advisory Board.
  • VANCOUVER, Wash., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a generative AI drug creation company, today announced the appointment of seasoned R&D executive Professor Sir Menelas “Mene” Pangalos to its Board of Directors and as co-chair of Absci’s Scientific Advisory Board.
  • Sir Pangalos was the Executive Vice President of BioPharmaceuticals R&D at AstraZeneca.
  • In his dual role, Sir Pangalos will also co-chair Absci’s Scientific Advisory Board.

Almirall Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases

Retrieved on: 
Thursday, December 21, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Regulatory T cell, Simcere Pharmaceutical, Immune system, Multimedia, BME, Greater, Natural killer T cell, Human, Pharmacokinetics, Cell, Safety, ALM, Almirall, NK

View the full release here: https://www.businesswire.com/news/home/20231221296013/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231221296013/en/
    Almirall HQ in Barcelona (Photo: Business Wire)
    ALM223 is a modified version of the protein IL-2 designed to selectively activate Regulatory T cells (Tregs).
  • It may therefore have potential to restore immune balance and prevent the immune cells from attacking the body’s own cells.
  • ALM223, previously referred to as SIM0278, had been developed by Simcere by utilizing their protein engineering platform.
  • Simcere also initiated the phase I development for the Chinese market in August 2023.

Absci Reports Business Updates and Third Quarter 2023 Financial and Operating Results

Retrieved on: 
Tuesday, November 14, 2023
IND, Investment, Insurance, Research, Therapy, Partnership, Immortalised cell line, R, AI, Almirall, TL1A, Cryptocurrency, Medical device, Pharmaceutical industry

VANCOUVER, Wash. and NEW YORK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today reported financial and operating results for the quarter ended September 30, 2023.

Key Points: 
  • Research and development expenses were $11.0 million for the third quarter of 2023 compared to $15.5 million for the corresponding prior year period.
  • Net loss was $22.0 million for the third quarter of 2023, as compared to $27.3 million for the corresponding prior year period.
  • Cash, cash equivalents, and short-term investments as of September 30, 2023 was $113.5 million, compared to $124.6 million as of June 30, 2023.
  • Absci continues to anticipate at least ten new Active Programs in 2023, based on the company's current partnership pipeline.

Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases

Retrieved on: 
Tuesday, November 14, 2023
ALM, Skin, CSO, Patient, De novo, Therapy, BME, Drug discovery, Partnership, R, Almirall, Medical device, AI

The partnership combines Absci’s Integrated Drug Creation™ platform with Almirall’s dermatological expertise with the goal of delivering life-changing medicines to patients, marking another step forward in AI drug creation.

Key Points: 
  • The partnership combines Absci’s Integrated Drug Creation™ platform with Almirall’s dermatological expertise with the goal of delivering life-changing medicines to patients, marking another step forward in AI drug creation.
  • The partnership represents Almirall’s first de novo AI drug collaboration, and it comes only months after Absci announced it could design and validate de novo therapeutic antibodies using its ‘zero-shot’ generative AI.
  • Under the terms of the partnership, Absci will apply its de novo generative AI technology to create and commercialize therapeutic candidates for two dermatological targets.
  • “We believe the collaboration will generate tremendous scientific and technical insights for using AI drug creation to treat chronic inflammatory diseases more broadly.

Almirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical Dermatology

Retrieved on: 
Tuesday, December 12, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, Messenger, ALM, Therapy, Skin, LNP, Patient, Vaccine, Almirall

Almirall, S.A. (ALM), a global pharmaceutical company focused on medical dermatology, and etherna, an mRNA/LNP technology platform company, announced today a multi-target alliance to discover and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer.

Key Points: 
  • Almirall, S.A. (ALM), a global pharmaceutical company focused on medical dermatology, and etherna, an mRNA/LNP technology platform company, announced today a multi-target alliance to discover and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer.
  • The alliance combines and leverages etherna’s innovative proprietary mRNA capabilities and LNP formulations with Almirall’s leading expertise in medical dermatology to accelerate discovery of novel treatment options.
  • Etherna and Almirall will work collaboratively on the research activities, while Almirall will lead clinical development and commercialization.
  • Under the terms of the agreement, etherna will receive upfront and technology access payments.

Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis

Retrieved on: 
Friday, November 17, 2023
Health, Other Health, Other Science, General Health, Science, Pharmaceutical, Biotechnology, Allergic conjunctivitis, Itch, Adolescence, ALM, Adherence, Safety, Hope, European Commission, Advocate, Disease, Teaching hospital, Civil service commission, TCS, Patient, Week, Doctor of Philosophy, Conjunctivitis, Atopic dermatitis, BME, Eli Lilly and Company, MD, Skin, Almirall, Human, Pharmaceutical industry, Vaccine, Dermatology

“The arrival of novel biologic treatments is marking a new paradigm in the management of atopic dermatitis.

Key Points: 
  • “The arrival of novel biologic treatments is marking a new paradigm in the management of atopic dermatitis.
  • The approval of lebrikizumab represents a leap forward in our ability to provide patients with an effective therapeutic option with demonstrated safety profile.
  • Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including atopic dermatitis, in Europe.
  • Almirall expects regulatory decisions for lebrikizumab in moderate-to-severe atopic dermatitis in additional European markets, including the United Kingdom and Switzerland.

Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases

Retrieved on: 
Tuesday, November 14, 2023
Biotechnology, Pharmaceutical, Health, ALM, Skin, CSO, Patient, De novo, Therapy, BME, Drug discovery, Partnership, R, Almirall, Medical device, AI

Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI ), a generative AI drug creation company, today announced a drug discovery partnership aimed to develop and commercialize AI-designed therapeutics to fight chronic and debilitating dermatological diseases.

Key Points: 
  • Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI ), a generative AI drug creation company, today announced a drug discovery partnership aimed to develop and commercialize AI-designed therapeutics to fight chronic and debilitating dermatological diseases.
  • The partnership combines Absci’s Integrated Drug Creation™ platform with Almirall’s dermatological expertise with the goal of delivering life-changing medicines to patients, marking another step forward in AI drug creation.
  • The partnership represents Almirall’s first de novo AI drug collaboration, and it comes only months after Absci announced it could design and validate de novo therapeutic antibodies using its ‘zero-shot’ generative AI.
  • Under the terms of the partnership, Absci will apply its de novo generative AI technology to create and commercialize therapeutic candidates for two dermatological targets.

Almirall: Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost-clear skin with lebrikizumab monthly maintenance dosing at two years

Retrieved on: 
Friday, October 20, 2023
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Almirall, Lilly, Eli Lilly and Company, AD, Aes, Eli Lilly, Adherence, Conference, Maintenance, Addiction severity index, Conditional sentence, IGA, Shingles, Abstract, The New England Journal of Medicine, Conjunctivitis, British Journal of Dermatology, Atopic dermatitis, Patient, Pharmaceutical industry, Dermatology, Tree-adjoining grammar, EASI

In ADjoin, 62 percent of patients reported adverse events (AEs), most of which were mild or moderate in severity.

Key Points: 
  • In ADjoin, 62 percent of patients reported adverse events (AEs), most of which were mild or moderate in severity.
  • The most common side effects of lebrikizumab were conjunctivitis, injection site reactions and shingles (herpes zoster).
  • “Results from ADjoin reinforce the strong efficacy and safety profile of lebrikizumab seen in the other Phase 3 atopic dermatitis trials.
  • Lilly has exclusive rights for development and commercialization of lebrikizumab in the U.S. and the rest of the world outside Europe.

Almirall's Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for Cyclosporine1

Retrieved on: 
Friday, October 13, 2023
Health, Managed Care, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Congress, EudraCT, Eli Lilly and Company, Knowledge, European Academies' Science Advisory Council, Advantage, CHMP, Abstract, Advocate, Ciclosporin, United Kingdom, BME, University, Week, Safety, ALM, Human, Disease, NRS, Psoriasis Area and Severity Index, Journal of the European Academy of Dermatology and Venereology, Almirall, Adolescence, Marketing, IGA, Adherence, AD, TCS, News, Overalls, EASI, Patient, Quality of life, Pharmaceutical industry, Dermatology, Venereology

Improvements in absolute skin response over 16 weeks for patients with moderate-to-severe AD treated with lebrikizumab or placebo were also shared.

Key Points: 
  • Improvements in absolute skin response over 16 weeks for patients with moderate-to-severe AD treated with lebrikizumab or placebo were also shared.
  • Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including AD, in Europe.
  • Almirall expects regulatory decisions for lebrikizumab in moderate-to-severe AD in additional European markets, including the United Kingdom and Switzerland in 2024.
  • † More information about the Phase 3 studies: ADvocate 1: EudraCT Number 2019-002932-10; NCT04146363; ADvocate 2: EudraCT Number 2019-002933-12; NCT04178967; ADhere: EudraCT Number 2019-004300-34; NCT04250337